John Wiley & Sons Blood and Marrow Transplantation Long Term Management Cover Blood and Marrow Transplantation Long Term Management Hematopoietic cell transplantation (HCT) prov.. Product #: 978-1-119-61269-8 Regular price: $142.06 $142.06 Auf Lager

Blood and Marrow Transplantation Long Term Management

Survivorship after Transplant

Savani, Bipin N. / Tichelli, Andre (Herausgeber)

Cover

2. Auflage Juni 2021
464 Seiten, Hardcover
Wiley & Sons Ltd

ISBN: 978-1-119-61269-8
John Wiley & Sons

Jetzt kaufen

Preis: 152,00 €

Preis inkl. MwSt, zzgl. Versand

Weitere Versionen

epubmobipdf

Blood and Marrow Transplantation Long Term Management

Hematopoietic cell transplantation (HCT) provides curative therapy for a variety of diseases. Over the past several decades, significant advances have been made in the field of HCT, to the point where HCT has become an integral part of treatment modality for a variety of hematologic malignancies and some nonmalignant diseases. HCT remains an important treatment option for a wide variety of hematologic and nonhematologic disorders, despite recent advances in the field of immunologic therapies. Factors driving this growth include expanded disease indications, greater donor options (expanding unrelated donor registries and haploidentical HCT), and accommodation of older and less fit recipients.

The development of less toxic pretransplant conditioning regimens, more effective prophylaxis of graft-versus-host disease (GVHD), improved infection control, and other advances in transplant technology have resulted in a rapidly growing number of transplant recipients surviving long-term free of the disease for which they were transplanted. The changes over decades in the transplant recipient population and in the practice of HCT will have almost inevitably altered the composition of the long-term survivor population over time. Apart from an increasingly older transplant recipient cohort, the pattern of transplant indications has shifted from the 1990s when chronic myeloid leukemia made up a significant proportion of allo-HCT indications. Changes in cell source, donor types, conditioning regimens, GVHD prophylaxis, and supportive care have all occurred, with ongoing reductions in both relapse and non-relapse mortality (NRM) have been demonstrated.

These patients have increased risks for a variety of late complications, which can cause morbidity and mortality. Most long-term survivors return to the care of their local hematologists/oncologists or primary care physicians, who may not be familiar with specialized monitoring and management of long complications after HCT for this patient population. As HCT survivorship increases, the focus of care has shifted to the identification and treatment of long-term complications that may affect quality of life and long-term morbidity and mortality.

Preventive care as well as early detection and treatments are important aspects to reducing morbidity and mortality in long-term survivors after allo-HCT. This second edition, Blood and Marrow Transplantation Long Term Management: Survivorship after Transplant, provides up-to-date information about diagnosis, screening, treatment, and long-term surveillance of long-term survivors after HCT.

List of contributors

Section 1 Late effects concepts

1 Introduction

Bipin N Savani and Andre Tichelli

2 International Blood and Marrow registries - trends on long-term data collection

Rachel Phelan, Jakob Passweg, Helen Baldomero, Minako Iida, Yoshiko Atsuta, Shinichiro Okamoto, Mahmoud Aljurf, Feras Alfraih, and Bronwen Shaw

3 Long-term transplant clinic setup

André Tichelli, Bipin Savani, Shahrukh K Hashmi, Navneet S Majhail, and Alicia Rovó

4 Telemedicine in patient care of long-term survivors

Catherine Lee, Mihkaila Wickline, and Mary Flowers

5 Long-term follow-up calendar

André Tichelli, Bipin N Savani, Shahrukh K Hashmi, Navneet S Majhail, and Alicia Rovó

6 Late effects after allogeneic hematopoietic stem cell transplantation

Shahrukh Hashmi and Yoshihiro Inamoto

7 Late effects after autologous hematopoietic stem cell transplantation

Rajshekhar Chakraborty and Betty Hamilton

8 Long-term follow-up of children

Paul Carpenter

9 Graft-versus-host disease and GvHD-associated late effects

David Michonneau, Aurélien Sutra-del-Galy, and Gérard Socié

10 Screening and prevention guidelines for hematopoietic cell transplant survivors

Neel S Batt, J Douglas Rizzo, and Navneet S Majhail

11 Biology of survivorship after BMT

Smita Bhatia

Section 2 Specific late effects

12 Secondary malignancies

Aurélien Sutra-del-Galy, David Michonneau, and Gérard Socié

13 Anti-infective prophylaxis, immunization and prevention of late infectious complications

Per Ljungman

14 Seasonal virus infections in recipients and exposure to family members

Nosha Farhadfar, Zeina Al-Mansour, and John Wingard

15 Monitoring and management of hepatitis B, C, and HIV infection before and after transplantation

Enric Carreras and Montserrat Rovira

16 Skin chronic graft-versus-host disease

Attilio Oliveri and Andrea Bacigalupo

17 Ocular complications

Alicia Rovó, André Tichelli, and Yoshihiro Inamoto

18 Oral and dental complications

Hildegard Greinix

19 Thyroid late complications

Juliana Matthews, Leslee Matheny, and Shubhada Jagasia

20 Pre-transplant considerations in gender, reproductive, and sexual health

Dana Shanis, Jeanne Murphy, Kate Debiec, Betty K Hamilton, Shawna Boyle, and Pamela Stratton

21 Post-transplant considerations in gender, reproductive, and sexual health

Jeanne Murphy, Dana Shanis, Kate Debiec, Betty K Hamilton, Shawna Boyle, and Pamela Stratton

22 Fertility issues, fertility preservation, and pregnancy outcome in long-term survivors

Alicia Rovó, Alison W Loren, André Tichelli, and Nina Salooja

23 Sexual dysfunction in long-term survivors

Rebecca Hunter, Sarah Thilges, Janna Gordon, Kristy Luke, Karla Cavazos, Emilee Moeke, Colleen Bruen, and Sunita Natha

24 Non-infectious pulmonary late complications

Ayman O Soubani

25 Cardiac and arterial complications

Alicia Rovó and André Tichelli

26 Cardiovascular risk factors

Kimberley Doucette and Minoo Battiwalla

27 Gastrointestinal complications

Sumona Bhattacharya, Steven Pavletic and Theo Heller

28 Hepatic complications

Christy Ann L Gilman Christopher Koh, Steven Pavletic, and Theo Heller

29 Renal complications

Insara Jaffer Sathick, and Sangeeta Hingorani

30 Post-Transplantation Bone Disease

Christine Ducan

31 Neurological late complications

Enrico Maffini

32 Neurogognitive dysfunction

David Buchbinder

33 Psychological distress

Anna Barata, Aasha I Hoogland and Heather SL Jim

34 Persistent chronic fatigue

Sandy Mitchell

35 Social issues

Sanghee Hong and Navneet Majhail

36 Health-related quality of life in adult and pediatric survivors

Lori Wiener, Jenny Hoag, and Tamryn Gray

Section 3 Supportive care and patients reported outcome

37 Immunosuppressive agents and monitoring in long-term survivors

Katie Culos and Katie Gatwood

38 Nutritional support and nutritional supplementation

Shigeo Fuji

39 Daily routines and healthy lifestyle guidelines

Melissa Logue

40 Prevalent psychosocial adjustment issues and solutions: lifestyle and social challenges

Katrina Stokes

41 Complementary and alternative medicine in HSCT

Ibrahim N Muhsen, Bipin N Savani, and Shahrukh Hashmi

42 Impact of adherence in outcome of long-term survivors

Corien Eeltink and Annika Kisch

43 Prominent role of allied health professionals

Catherine E Lucid

44 Patient reported outcome

Hélène Schoemans

45 Caregivers of long-term survivors

Angela Moreschi Woods

46 Patient's perspective: memory of a recovered lymphomaniac

Michael Brown

Appendix 1 Commonly used transplant-related medications in long-term survivors

Katie Culos and Katie Gatwood

Appendix 2 The eGVHD App

Hélène Schoemans

Index
About the Editors

Bipin N. Savani is Professor of Medicine and Director of Long-Term Transplant and Survivorship Clinic at Vanderbilt University Medical Center and Veterans Affairs Medical Center, Nashville, TN, USA.

André Tichelli is Professor Emeritus of Hematology, Division of Hematology, University Hospital Basel, Switzerland.

B. N. Savani, Vanderbilt University Medical Center, Nashville, TN; A. Tichelli, University Hospital Basel, Switzerland